Aspen has reported a 28% rise in annual normalised headline earnings per share from continuing operations, in constant-currency terms, despite flat revenue as efficiency gains improved profitability. Business Day TV spoke to Stephen Saad, group CEO of Aspen Pharmacare, for more insight.Would you like to comment on this article?Sign up (it's quick and free) or sign in now.Sign UpLog InPlease read our Comment Policy before commenting.